M4MM

Compass Builds a Commercial Case for COMP360

NEW YORK – Compass Pathways is advancing COMP360, its proprietary synthetic psilocybin for treatment-resistant depression (TRD), through a rolling FDA New Drug Application, with a commercial launch targeted for H1 2027. Alongside the regulatory push, ...

Compass Builds a Commercial Case for COMP360

NEW YORK – Compass Pathways is advancing COMP360, its proprietary synthetic psilocybin for treatment-resistant depression (TRD), through a rolling FDA New Drug Application, with a commercial launch targeted for H1 2027. Alongside the regulatory push, ...

Dutch Medical Cannabis Giant Bedrocan Goes Bankrupt

GRONINGEN – The District Court of Northern Netherlands officially declared Bedrocan bankrupt, after the company sought a suspension of payments in late September, ending a more than two-decade run as the country's sole licensed medical ...

DEA Opens Schedule III Registration Path for Medical Cannabis Operators

WASHINGTON – The Drug Enforcement Administration’s Diversion Control Division has launched the application process, making DEA Form 225 available to state-licensed medical Cannabis manufacturers, distributors, and analytical labs. Manufacturers cover cultivation, production, processing, packaging, labeling ...

Subscribe To Our Newsletter